1. Ferreira ME, Satagopan JM, Yandell BS, Williams PH, Osborn TC. Mapping quantitative loci controlling vernalization requirement and flowering time in Brassica napus. Theor Appl Genet 1995; 90: 727-732.
2. Teutonico RA, Ferreira ME, Satagopan JM, Yandell BS, Palta JP, Osborn TC. Genetic analysis and mapping of genes controlling freezing tolerance in oilseed. Molecular Breeding 1995; 1: 329-339.
3. Satagopan JM, Yandell BS, Newton MA, Osborn TC. A Bayesian approach to detect quantitative trait loci via Markov chain Monte Carlo. Genetics 1996; 144: 805-816. [PubMed Abstract]
4. Begg CB, Satagopan JM, Berwick M. A new strategy for evaluating the impact of epidemiologic risk factors for cancer with application to melanoma. J Amer Stat Assoc 1998; 93: 415-426.
5. Pasche B, Luo Y, Rao PH, Nimer SD, Dimitrovsky E, Caron P, Luzzatto L, Offit K, Cordon-Cardo C, Renault B, Satagopan JM, Murty VVVS, Massague J. The type I TGF\beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant with a polyalanine tract. Cancer Res 1998; 58: 2727-2732. [PubMed Abstract]
6. Redston M, Nathanson KL, Yuan ZQ, Neuhausen SL, Satagopan J, Wong N, Yang D, Nafa D, Abrahamson J, Ozcelik H, Antin-Ozerkis D, Andrulis I, Daly M, Pinsky L, Schrag D, Gallinger S, Kaback M, King MC, Woodage T, Brody LC, Godwin A, Warner E, Weber B, Foulkes W, Offit K. The APC I1307K allele and breast cancer risk (Letter). Nat Genet 1998; 20: 13-14. [PubMed Abstract]
7. Cheung IY, Cheung N-KV, Ghossein RA, Satagopan JM, Bhattacharya S, Coit DG. Association between molecular detection of GAGE and survival in patients with malignant melanoma: a retrospective cohort study. Clin Cancer Res 1999; 5: 2042-2047. [PubMed Abstract]
8. Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, Brener D, Yang D, Kirstein L, Oddoux C, Ostrer H, Jhanwar S, Luzzatto L, Massague J, Offit K. T$\beta$R-I(6A) is a candidate tumor susceptibility allele. Cancer Res 1999; 59: 5678-5682. [PubMed Abstract]
9. Robson M, Levin D, Federici M, Satagopan J, Bogolminyi F, Heerdt A, Borgen P, McCormick B, Hudis C, Norton L, Boyd J, Offit K. Breast conservation therapy for invasive breast cancer in Ashkenazi Jewish women with BRCA gene founder mutations. J Natl Cancer Inst 1999; 91: 2112-2117. [PubMed Abstract]
10. Levine DA, Lin O, Barakat RR, Robson ME, McDermot D, Cohen L, Satagopan J, Offit K, Boyd J. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 2001; 80: 395-398. [PubMed Abstract]
11. Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB. The lifetime risk of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001; 10: 467-473. [PubMed Abstract]
12. Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P, Norton L, Offit K. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20: 1260-1268. [PubMed Abstract]
13. Satagopan JM, Verbel DA, Venkatraman ES, Offit KE, Begg CB. Two-stage designs for gene-disease association studies. Biometrics 2002; 58: 163-170. [PubMed Abstract]
14. Kauff ND, Satagopan JM, Scheuer L, Robson ME, Castiel M, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Offit K. Risk-reducing salpingo-oophorectomy in women with BRCA1 and BRCA2 mutations. N Eng J Med 2002; 346: 1609-1615. [PubMed Abstract]
15. LaTulippe E, Satagopan JM, Smith A, Scher H, Scardino P, Reuter V, Gerald WL. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002; 62: 4499-4506. [PubMed Abstract]
16. Offit K, Gilad S, Paglin S, Kolachana P, Roisman L, Nafa K, Yeugelewitz V, Gonzales M, Robson M, McDermott D, Pierce H, Kauff N, Einat P, Jhanwar S, Satagopan J, Oddoux C, Ellis N, Skaliter R, Yahalom J. Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. Clin Cancer Res 2002; 8: 3813-3819. [PubMed Abstract]
17. Satagopan JM, Boyd J, Kauff N, Robson M, Scheuer, L, Narod S, Offit KE. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002; 8: 3776-3781. [PubMed Abstract]
18. Gruber SB, Ellis NA, Scott KK, Almog R, Kolachana P, Bonner JD, Kirchhoff T, Tomsho LP, Nafa K, Pierce H, Low M, Satagopan J, Rennert H, Huang H, Greenson JK, Groden J, Rapaport B, Shia J, Johnson S, Gregersen PK, Harris CC, Boyd J, Rennert G, Offit K. BLM heterozygosity and the risk of colorectal cancer (Brevia). Science 2002; 297: 2013. [PubMed Abstract]
19. Kutler DI, Auerbach AD, Satagopan JM, Giampietro PF, Batish SD, Shah JP, Singh B. High incidence of head and neck squamous cell carcinoma (HNSCC) in patients with Fanconi anemia (FA). Archives of Otolaryngol 2003; 129: 106-112. [PubMed Abstract]
20. Kutler DI, Singh B, Satagopan JM, Berwick M, Giampietro PF, Auerbach AD. A 20 year perspective of the International Fanconi Anemia Registry (IFAR). Blood 2003; 101: 1249-1256. [PubMed Abstract]
21. Offit K, Pierce H, Kirchhoff T, Kolachana P, Rapaport B, Gregersen P, Johnson S, Yosspowitch O, Huang H, Satagopan J, Robson M, Scheuer L, Nafa K, Ellis N. Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 2003; 4:1. [PubMed Abstract]
22. Satagopan JM, Panageas KS. A statistical perspective on gene expression data analysis. Stat Med 2003; 22: 481-499.[PubMed Abstract]
23. Satagopan JM, Smith AD. Statistical methods in genomics research. Heart Drug 2003; 3: 48-60.
24. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, Noy A, Portlock CS, Straus DJ, Yahalom J, Nimer SD, Moskowitz CH. The second-line age-adjusted prrognostic index (sAAIPI) predicts autologous stem cell transplant (ASCT) outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989-1996. [PubMed Abstract]
25. Yossepowitch O, Olvera N, Satagopan JM, Huang H, Jhanwar S, Ben-Porat L, Rapaport B, Boyd J, Offit K. BRCA1 and BRCA2 germline mutations in lymphoma patients. Leuk Lymphoma 2003; 44: 127-131. [PubMed Abstract]
26. Ulaner GA, Hung H-Y, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR, Ladanyi M. Absense of telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 2003; 63: 1759-1763. [PubMed Abstract]
27. Satagopan JM, Elston RC. Optimal two-stage genotyping in population-based association studies. Genet Epidemiol 2003; 25: 149-157. [PubMed Abstract]
28. Kutler DI, Wreesmann VB, Goberdhan A, Ben-Porat L, Satagopan J, Ngai I, Huvos AG, Giampietro P, Levran O, Pujara K, Diotti R, Carlson D, Huryn LA, Auerbach AD, Singh B. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi Anemia patients. J Natl Cancer Inst 2003; 95: 1718-1721. [PubMed Abstract]
29. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Begin LR, Offit K, Foulkes WD. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1 / BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004; 6: R8-R17. [PubMed Abstract]
30. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164: 217-227. [PubMed Abstract]
31. Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Rapaport H, Nafa K, Ellis NA, Offit K. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 2004; 96: 68-70. [PubMed Abstract]
32. Wagner JE, Tolar J, Levran O, Scholl T, Deffenbaugh A, Satagopan J, Ben-Porat L, Mah K, Batish SD, Kutler DI, MacMillam ML, Hanenberg H, Auerbach AD. Germline mutation in BRCA2: Shared genetic susceptibility to breast cancer, early onset leukemia and Fanconi anemia. Blood 2004; 103: 3226-3229. [PubMed Abstract]
33. Satagopan JM, Venkatraman ES, Begg CB. Two-stage designs for gene-disease association studies with sample size constraints. Biometrics 2004; 60: 589-597. [PubMed Abstract]
34. Satagopan JM, Ben-Porat L, Berwick M, Robson ME, Kutler DI, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer 2004; 91: 1229-1235. [PubMed Abstract]
35. Shuch B, Mikhail M, Satagopan J, Lee P, Yee H, Chang C, Cordon-Cardo C, Taneja S, Osman I. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol 2004; 22: 4725-4728. [PubMed Abstract]
36. Shaffer DR, Viale A, Ishiwata R, Leversha M, Olgac S, Manova K, Satagopan J, Scher H, Koff A. Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate. Proc Natl Acad Sci 2005;102:210-215. [PubMed Abstract]
37. Sen S, Satagopan JM, Churchill GA. Quantitative trait locus study design from an information perspective. Genetics 2005;170:447-464. [PubMed Abstract]
38. Stephenson AJ, Smith A, Kattan MW, Satagopan J, Reuter VE, Scardino PT, Gerald WL. Integration of gene expression profiling and clinical variables to predict prostate cancer recurrence after radical prostatectomy. Cancer 2005;104:290-298. [PubMed Abstract]
39. S Kesh, NY Mensah, P Peterlongo, D Jaffe, K Hsu, M van den Brink, R O'reilly, E Pamer, J Satagopan, GA Papanicolaou. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Annals of the New York Academy of Sciences 2005; 1062: 95-103. [PubMed Abstract]
40. AD Berger, J Satagopan, P Lee, SS Taneja, I Osman. Differences in clinicopathologic features of prostate cancer between black and white patients treated in the 1990s and 2000s. Urology 2006; 67: 120-124.
41. DA Douglas, H Zhong, JY Ro, C Oddoux, A Berger, MR Pincus, JM Satagopan, WL Gerald, HI Scher, P Lee, I Osman. Novel mutations of the epidermal growth factor receptor in localized prostate cancer. Frontiers in Bioscience 2006; 11: 2518-2525. [PubMed Abstract]
42. FC Maluf, C Cordon-Cardo, DA Verbel, JM Satagopan, MG Boyle, H Herr, DF Bajorin. Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. Annals of Oncology 2006 Nov;17(11):1677-86. Epub 2006 Sep 19. [PubMed Abstract]
